The COVID-19 pandemic’s propulsion of widespread telehealth adoption has ResMed (NYSE:RMD) eyeing remote technologies for the next phase of its sleep and respiratory businesses.
The president of that business for the San Diego-based company, Jim Hollingshead, told Medical Design & Outsourcing in a recent interview that the future lies with remote care and digital health offerings.
“Right before the crisis, we got up to a point where home sleep testing was done at about 40% of the time,” Hollingshead said. “Right now, I think it’s more like 50/50 because of the way sleep labs are using home testing instead of bringing people in.”
ResMed’s remote diagnostic technology includes mail-order delivery of an elastic belt that wraps around the user’s chest and connects to a pulse oximeter and a cannular tube that goes over the ears and sticks on the nose. The home sleep test looks for oxygen saturation while the belt measures chest movement as the user breathes.
Get the full story at our sister site, Medical Design & Outsourcing.